Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT04380636 2026-05-15

MK-7339-012

Phase 3 Active not recruiting

870 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06217757 2026-05-05

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Phase 1/2 Recruiting

45 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02498613 2026-05-01

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2 Active not recruiting

122 enrolled 16 charts

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03775486 2026-05-01

ORION

Phase 2 Active not recruiting

401 enrolled 26 charts

Thoracic

Non-small Cell Lung Cancer NSCLC

NCT02734004 2026-04-20

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT04375267 2026-04-14

LuPARP

Phase 1 Completed

18 enrolled

EndocrineNETOther solid neoplasmThoracic

Mesothelioma, Thymoma, Neuroendocrine Tumors

NCT06130254 2026-04-09

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Phase 1 Terminated

1 enrolled

Other solid neoplasmThoracic

Advanced Solid Tumor

NCT02679963 2026-04-06

PIPSeN

Phase 2 Terminated

180 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

25 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Phase 1/2 Not yet recruiting

626 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04550104 2025-12-19

CONCORDE

Phase 1 Recruiting

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04728230 2025-12-18

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

Phase 1/2 Active not recruiting

63 enrolled

Thoracic

Lung Neoplasms

NCT05568212 2025-12-01

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Phase 2 Recruiting

176 enrolled

Thoracic

Non-small-cell Lung Cancer Patients

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

Phase 1/2 Completed

220 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Phase 1/2 Completed

45 enrolled 30 charts

GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT05623319 2025-06-24

THOR

Phase 2 Recruiting

60 enrolled

Thoracic

SCLC,Extensive Stage

Clinical Trials

MK 7339-013

MK-7339-012

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

ORION

MEDIOLA

LuPARP

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

PIPSeN

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

QLS5132 Combination Therapy in Advanced Solid Tumors

CONCORDE

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

HUDSON

Study to Evaluate CCS1477 in Advanced Tumours

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

THOR